HC Wainwright Adjusts Price Target for Aardvark Therapeutics
HC Wainwright has lowered its price target for Aardvark Therapeutics from $4.00 to $2.00 while maintaining a Neutral rating.
Stocks · News reference
Why Scholar Rock Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket
Scholar Rock surged 11.9% after FDA approved ISEMBYLD for SMA; Scinai, Intercont and Rum led premarket gainers, while Picocela fell.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Aardvark Therapeutics Reports Exploratory Data from Terminated HERO and OLE Trials
Aardvark Therapeutics released exploratory efficacy and safety data from its previously terminated Phase 3 HERO and open-label extension trials for ARD-101.
FDA Lifts Clinical Hold on Aardvark Therapeutics' ARD-101
The U.S. Food and Drug Administration has lifted the clinical hold on Aardvark Therapeutics' investigational new drug application for ARD-101, intended for treating hyperphagia in Prader-Willi Syndrome.
8-K filing — Aardvark Therapeutics, Inc. (AARD)
Filed: 2026-10-23 AccNo: 0001193125-26-429509 Size: 11 MB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Biodexa Pharmaceuticals Announces 1-for-8 Reverse Stock Split
Biodexa Pharmaceuticals has announced a 1-for-8 reverse stock split of its shares, scheduled to take effect on October 26, 2026.
Biodexa Pharmaceuticals shares are trading higher after the company announced it enrolled 100 patients in its registrational Phase 3 trial of eRapa in Familial Adenomatous Polyposis.